Drug Database
VI

vincristine sulfate

✓ Approved

Pierre Fabre S.A. · Small Molecule · Small Molecule

What is vincristine sulfate?

vincristine sulfate is a small molecule developed by Pierre Fabre S.A.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

CompanyPierre Fabre S.A.
Drug ClassSmall Molecule
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Pierre Fabre S.A.

Therapeutic Indications

vincristine sulfate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Neoplasm malignant✓ Approved

Related Research Articles

PubMedEye (London, England)2026-10-07

Retinoblastoma management: achieving high standards of care.

Shields Carol L CL, Medina Robert J RJ, Botros Salaam S, Bechara Ghobril Antonio A et al.

The current management of retinoblastoma involves chemotherapy by the intravenous, intra-arterial, intravitreous or intra-aqueous delivery routes. These routes can adequately control solid tumour, subretinal seeds, vitreous seeds or aqueous seeds. Intravenous chemotherapy using vincristine, etoposide and carboplatin is commonly used for retinoblastoma control. According to the International Classification of Retinoblastoma, intravenous chemotherapy provides globe salvage with tumour control in 96% of Group A, 90% of Group B and Group C, 68% of Group D and 32% of Group E eyes. Intra-arterial chemotherapy, using melphalan, topotecan and/or carboplatin with delivery from the femoral artery up to the ophthalmic artery to the eye, is particularly used for unilateral retinoblastoma. This alternative has more localised ocular complications but offers more powerful tumour control. Intravitreal chemotherapy, using melphalan and topotecan, can control vitreous seeding, but most specialists employ high-dose topotecan for control of vitreous seeds and some solid tumours and even subretinal seeds. Intra-aqueous chemotherapy, using melphalan or topotecan and can be effective for aqueous seeding. There is still a role for plaque radiotherapy in non-chemotherapy-responsive tumours and enucleation for massive disease that doesn't fully respond to chemotherapy or demonstrates high-risk disease. The management of retinoblastoma has evolved to the current day with several routes of chemotherapy delivery.

PMID 42839089
Read full article →
PubMedFrontiers in nutrition2026-10-07

Real world evidence for glucosamine-chondroitin-calcium supplementation on joint pain.

Ju Jingmeng J, Li Zhongxia Z, Yang Jialu J, Deng Chaoming C et al.

Joint and bone diseases are major causes of morbidity worldwide. While glucosamine sulfate (GS) and chondroitin sulfate (CS) have demonstrated benefits in severe degenerative joint conditions, real-world evidence on the use patterns and reported outcomes of their combination with calcium (GCC) among individuals with mild-to-moderate joint discomfort remains limited. This real-world study enrolled 9,090 adults who used GCC for ≥1 month and completed an online questionnaire; pre- and post-use symptom scores were analyzed among participants reporting joint symptoms or back pain. Linear mixed-effects models adjusted for demographics, lifestyle, comorbidities, medications, and other dietary supplement use. After GCC use, joint pain, stiffness, swelling, inflexibility and back pain scores were significantly lower than pre-use scores, with mean changes of -1.74 (95% CI: -1.81 to -1.68) for joint pain and -1.37 (95% CI: -1.45 to -1.28) for back pain (all P < 0.001), although none of the mean changes reached the pre-specified primary two-point minimal clinically important difference. Notably, intake at or above the recommended dosage was associated with more favorable changes in pain, stiffness, and back pain scores. Longer intake duration, better adherence, and physical activity were also associated with more favorable changes in some symptom scores. Self-reported adverse events were rare (5.61%), predominantly gastrointestinal. Although the mean changes did not reach the pre-specified primary two-point minimal clinically important difference, GCC use was associated with lower joint discomfort and back pain scores, and self-reported adverse events were rare.

PMID 42840557
Read full article →
PubMedBMB reports2026-10-07

Post-translational control of synaptic adhesion molecules: molecular mechanisms and disease implications.

Yun Seo-Young SY, Song Ji-Hye JH, Han Kyung Ah KA

Synaptic cell adhesion molecules (SAMs) are crucial for organizing synapse formation, maturation, and plasticity. No longer considered static structural links between pre- and postsynaptic membranes, SAMs are now understood to be dynamic signaling platforms whose functions are precisely controlled by various post-translational modifications (PTMs). For instance, conventional N- and O-linked glycosylation regulates protein folding and surface trafficking, whereas proteoglycan modification by heparan sulfate (HS) contributes to extracellular recognition and trans-synaptic interactions. Meanwhile, phosphorylation and dephosphorylation influence scaffold recruitment, synapse type specificity, and activity-dependent signaling. Additionally, proteolytic processing and ubiquitination manage the turnover, endocytosis, and signaling duration of adhesion complexes, allowing for rapid changes in synaptic connectivity. This review synthesizes recent progress on how these PTMs regulate SAMs and neurotrophin receptors across different scales, from individual synapses to entire neural circuits. We also discuss how PTM dysregulation contributes to neurodevelopmental and neuropsychiatric disorders and highlight the possibility that interactions among distinct PTMs may form a combinatorial regulatory code that further diversifies synaptic adhesion signaling, although this concept requires further investigation.

PMID 42839611
Read full article →
PubMedFrontiers in pharmacology2026-10-07

Ulcerative colitis therapeutic effects and pharmacokinetics of flexible quercetin nanocrystals prepared with geniposide assistance.

Lv Wei W, Liu Haobo H, Feng Haixian H, Xue Huiqin H et al.

This study aimed to improve the oral bioavailability and therapeutic efficacy of quercetin (QUE) against ulcerative colitis (UC) by formulating flexible quercetin nanocrystals (QUE-NCs) with the assistance of geniposide (Gen). QUE-NCs were prepared via an antisolvent precipitation method leveraging the interaction between QUE and Gen. Therapeutic efficacy was evaluated in a dextran sulfate sodium (DSS)-induced UC mouse model using disease activity index (DAI), colon histopathology (H&E), and ELISA-based biochemical assays. Biosafety was assessed through serum biochemistry, organ indices, and histopathological examination. An HPLC method was developed and validated for quantifying QUE in rat plasma, followed by a pharmacokinetic study in Wistar rats. QUE-NCs exhibited a flexible rod-like morphology and significantly alleviated UC symptoms, including weight loss, fecal occult blood, and colonic damage. Treatment with QUE-NCs reduced pro-inflammatory cytokines (TNF-α: 173.51 pg·mL-1; IL-6: 32.55 pg·mL-1), restored anti-inflammatory IL-10 levels (126.37 pg·mL-1), and suppressed oxidative stress markers (MPO: 579.95 pg·mL-1; MDA: 62.44 nmol·g-1; iNOS: 6.78 ng·mL-1). The nanocrystal formulation demonstrated excellent biosafety at the tested dose and significantly enhanced QUE's oral bioavailability (294.42% relative to raw QUE). Gen-assisted formulation of QUE-NCs improves both the oral absorption and anti-UC efficacy of QUE, offering a promising nanostrategy for flavonoid-based therapeutic development.

PMID 42840060
Read full article →
PubMedJMA journal2026-10-07

The Amyloid State of Mutant p53 in Cancer.

Iwahashi Naoyuki N, Ino Kazuhiko K

Mutations in TP53, the most frequently altered gene in human cancer, have long been interpreted within a genetic framework centered on loss of tumor-suppressive function and dominant-negative inhibition. Here, we highlight an emerging paradigm in which mutant p53 operates as a protein conformational disease. A growing body of evidence demonstrates that many cancer-associated p53 mutants adopt an amyloid-like state driven by structural destabilization of the DNA-binding domain, exposing aggregation-prone sequences that nucleate β-sheet-rich oligomers and fibrils. These aggregates exhibit prion-like properties, enabling templated misfolding and self-propagation of aberrant p53 conformations within cells. Beyond intracellular accumulation, recent experimental findings suggest that p53 aggregates may be transferred between cells via extracellular vesicles and heparan sulfate proteoglycan-mediated uptake. However, whether such transfer results in sustained tissue-level propagation within human tumors remains to be established. This proposed "seed-and-spread" model provides an emerging conceptual framework for understanding tumor heterogeneity and disease evolution beyond genetic alterations alone. Clinically, amyloid-like p53 aggregates have been detected in multiple malignancies, including ovarian, breast, and lung cancers, where they are associated with aggressive phenotypes, therapeutic resistance, and poor patient outcomes. These observations indicate that the conformational state of p53 represents a critical but previously underappreciated determinant of tumor behavior. Reframing mutant p53 as a self-propagating oncogenic proteinopathy bridges cancer biology with the principles of neurodegenerative disease and opens new therapeutic opportunities. Targeting the aggregation process, restoring native folding, promoting degradation of misfolded p53, or interrupting intercellular transmission may enable direct intervention against TP53-mutant cancers, which account for nearly half of all human malignancies. This perspective establishes protein misfolding and conformational propagation as central drivers of oncogenesis and highlights a new frontier for precision oncology.

PMID 42840663
Read full article →
PubMedVeterinary medicine international2026-10-07

Screening of Respiratory Tract-Associated Nematodes in Moroccan Dogs: Focus on Eucoleus boehmi.

Idrissi Houda H, ElHamiani Khatat Sarah S, Duchateau Luc L, Daminet Sylvie S et al.

Dogs can harbor a range of respiratory tract helminths which can cause clinical signs varying from asymptomatic to serious diseases. Lately, these parasites, notably Eucoleus spp. and Angiostrongylus vasorum, received considerable attention because of their spread in previously nonendemic regions, likely facilitated by several factors such as increased animal movements changes in the distribution and urbanization of wild canid reservoirs, along with climatic and environmental changes. This study aimed to assess the presence and dissemination of these helminths by investigating, for the first time in Morocco, the seroprevalence of A. vasorum and the fecal occurrence of Eucoleus spp. eggs in dogs. Overall, 318 fecal samples collected from dogs across different geographical areas of Morocco were examined using two fecal flotation techniques, centrifugal flotation with 33% zinc sulfate (ZnSO4) and simple flotation with Sheather's sugar solution. Additionally, A. vasorum antigen detection was performed on 286 blood samples using an in-clinic serological test (Angio Detect Test, IDEXX Laboratories). A complete blood count was subsequently performed in dogs that tested positive. Results revealed the occurrence of Eucoleus boehmi eggs in three military working dogs (0.94%), with two being asymptomatic and one showing a mucous nasal discharge. All had mild to moderate eosinophilia (1.33-3.18 K/μL). With regard to the serological assays, all dogs tested negative for A. vasorum antigens. These preliminary findings provide initial evidence of the geographic spread of E. boehmi, suggesting that veterinarians in Morocco should include this infection in the differential diagnosis of dogs displaying upper respiratory tract symptoms. By contrast, despite the absence of dogs seropositive to A. vasorum, the disease cannot be excluded until a better understanding of its distribution is established. Hence, further studies involving larger canine populations across different regions and combining multiple diagnostic methods, including advanced molecular techniques, are highly recommended.

PMID 42840337
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about vincristine sulfate